Tinnitus,
500 patients in an Argentine study!
Piddling numbers (only ivermectin used not azithromycin and zinc as well ) and yet half as many ivermectin users ended up hospitalized,
14 to 21.
Proves nothing . See their study limitations below. Results
The mean age was 42 years (SD ± 15.5) and the median time since symptom onset to the inclusion was 4 days [interquartile range 3–6]. The primary outcome of hospitalization was met in 14/250 (5.6%) individuals in ivermectin group and 21/251 (8.4%) in placebo group (odds ratio 0.65; 95% confidence interval, 0.32–1.31; p = 0.227). Time to hospitalization was not statistically different between groups. The mean time from study enrollment to invasive mechanical ventilatory support (MVS) was 5.25 days (SD ± 1.71) in ivermectin group and 10 days (SD ± 2) in placebo group, (p = 0.019). There were no statistically significant differences in the other secondary outcomes including polymerase chain reaction test negativity and safety outcomes. Limitations
Low percentage of hospitalization events, dose of ivermectin and not including only high-risk population.
